These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22463610)

  • 41. Endocannabinoid control of food intake and energy balance.
    Di Marzo V; Matias I
    Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cannabinoid receptor antagonists and obesity.
    Black SC
    Curr Opin Investig Drugs; 2004 Apr; 5(4):389-94. PubMed ID: 15134279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cannabinoid-1 receptor antagonists in type-2 diabetes.
    Scheen AJ
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):535-53. PubMed ID: 18054734
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
    Steinberg BA; Cannon CP
    Am J Cardiol; 2007 Dec; 100(12A):27P-32P. PubMed ID: 18154743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Seo HJ; Kim MJ; Song KS; Lee SH; Jung ME; Kim MS; Park HJ; Yoo J; Chang CH; Kim J; Lee J
    Future Med Chem; 2009 Aug; 1(5):947-67. PubMed ID: 21426091
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
    Ward SJ; Raffa RB
    Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
    [No Abstract]   [Full Text] [Related]  

  • 47. [Rimonabant. Risk of depression has not been finally clarified].
    Kreutzkamp B
    Med Monatsschr Pharm; 2008 May; 31(5):191-2. PubMed ID: 18552079
    [No Abstract]   [Full Text] [Related]  

  • 48. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
    Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
    Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The endocannabinoid system as a novel approach for managing obesity.
    Lillo JL
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP; Golay A; Sjöström L;
    N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity.
    McLaughlin PJ
    Behav Pharmacol; 2012 Sep; 23(5-6):537-50. PubMed ID: 22743603
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rimonabant: more than an anti-obesity drug?
    Costa B
    Br J Pharmacol; 2007 Mar; 150(5):535-7. PubMed ID: 17245359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
    Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C
    Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
    Padwal RS; Majumdar SR
    Lancet; 2007 Jan; 369(9555):71-7. PubMed ID: 17208644
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
    Boekholdt SM; Jukema JW; Peters RJ
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [New drugs; rimonabant].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rimonabant and progression of atherosclerosis in obese persons.
    Dora JM; Scheffel RS
    JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
    [No Abstract]   [Full Text] [Related]  

  • 59. Recent advances in the research and development of CB1 antagonists.
    Smith RA; Fathi Z
    IDrugs; 2005 Jan; 8(1):53-66. PubMed ID: 15650943
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rimonabant--a selective CB1 antagonist.
    Boyd ST; Fremming BA
    Ann Pharmacother; 2005 Apr; 39(4):684-90. PubMed ID: 15755787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.